Literature DB >> 14982796

In vitro activity of daptomycin against gram-positive European clinical isolates with defined resistance determinants.

Ad C Fluit1, Franz-Josef Schmitz, Jan Verhoef, Dana Milatovic.   

Abstract

The in vitro activity of daptomycin against 337 gram-positive European clinical isolates with known resistance genes was determined. The MIC ranges for Staphylococcus aureus, enterococci, pneunococci, and streptococci were 0.03 to 1, 0.25 to 8, 0.12 to 1, and 0.06 to 8 micro g/ml, respectively. For only one streptococcus isolate and seven enterococcus isolates was the MIC 8 micro g/ml.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14982796      PMCID： PMC353156          DOI： 10.1128/AAC.48.3.1007-1011.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  21 in total

1.  In vitro bactericidal activity of daptomycin against staphylococci.

Authors:  Peter C Fuchs; Arthur L Barry; Steven D Brown
Journal:  J Antimicrob Chemother       Date:  2002-03       Impact factor: 5.790

2.  Activity of daptomycin against Gram-positive pathogens: a comparison with other agents and the determination of a tentative breakpoint.

Authors:  R Wise; J M Andrews; J P Ashby
Journal:  J Antimicrob Chemother       Date:  2001-10       Impact factor: 5.790

3.  In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers.

Authors:  A L Barry; P C Fuchs; S D Brown
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

4.  Different erythromycin resistance mechanisms in group C and group G streptococci.

Authors:  J Kataja; H Seppälä; M Skurnik; H Sarkkinen; P Huovinen
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

5.  The prevalence of aminoglycoside resistance and corresponding resistance genes in clinical isolates of staphylococci from 19 European hospitals.

Authors:  F J Schmitz; A C Fluit; M Gondolf; R Beyrau; E Lindenlauf; J Verhoef; H P Heinz; M E Jones
Journal:  J Antimicrob Chemother       Date:  1999-02       Impact factor: 5.790

6.  Epidemiology and susceptibility of 3,051 Staphylococcus aureus isolates from 25 university hospitals participating in the European SENTRY study.

Authors:  A C Fluit; C L Wielders; J Verhoef; F J Schmitz
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

7.  The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates.

Authors:  A King; I Phillips
Journal:  J Antimicrob Chemother       Date:  2001-08       Impact factor: 5.790

8.  In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains.

Authors:  M J Rybak; E Hershberger; T Moldovan; R G Grucz
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

9.  Lipoteichoic acid as a new target for activity of antibiotics: mode of action of daptomycin (LY146032).

Authors:  P Canepari; M Boaretti; M M Lleó; G Satta
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

10.  Comparative In vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens.

Authors:  D R Snydman; N V Jacobus; L A McDermott; J R Lonks; J M Boyce
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191
View more
  8 in total

1.  In vitro activity of daptomycin against methicillin-resistant Staphylococcus aureus, including heterogeneously glycopeptide-resistant strains.

Authors:  Bram M W Diederen; Inge van Duijn; Piet Willemse; Jan A J W Kluytmans
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

2.  In vitro activities of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillin-resistant Staphylococcus aureus strains from a national survey of Belgian hospitals.

Authors:  Olivier Denis; Ariane Deplano; Claire Nonhoff; Marie Hallin; Raf De Ryck; Raymond Vanhoof; Ricardo De Mendonça; Marc J Struelens
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

Review 3.  Diabetic foot infections: microbiological aspects, current and future antibiotic therapy focusing on methicillin-resistant Staphylococcus aureus.

Authors:  Andreas Ambrosch; Simone Haefner; Edward Jude; Ralf Lobmann
Journal:  Int Wound J       Date:  2011-08-23       Impact factor: 3.315

4.  Potential chitosan-coated alginate nanoparticles for ocular delivery of daptomycin.

Authors:  J R Costa; N C Silva; B Sarmento; M Pintado
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-03-10       Impact factor: 3.267

5.  Multicenter evaluation of the Etest and disk diffusion methods for differentiating daptomycin-susceptible from non-daptomycin-susceptible Staphylococcus aureus isolates.

Authors:  Laura A Jevitt; Grace M Thorne; Maria M Traczewski; Ronald N Jones; John E McGowan; Fred C Tenover; Steven D Brown
Journal:  J Clin Microbiol       Date:  2006-09       Impact factor: 5.948

6.  In vitro activity of daptomycin against Staphylococci isolated from bacteremia and community-onset skin and soft tissue infections in France: data from two nationwide studies.

Authors:  O Gallon; C Guillet-Caruba; B Lamy; F Laurent; F Doucet-Populaire; J-W Decousser
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-06-06       Impact factor: 3.267

Review 7.  Daptomycin: a review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteraemia.

Authors:  Philip I Hair; Susan J Keam
Journal:  Drugs       Date:  2007       Impact factor: 9.546

8.  Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005).

Authors:  Helio S Sader; Amy A Watters; Thomas R Fritsche; Ronald N Jones
Journal:  BMC Infect Dis       Date:  2007-04-18       Impact factor: 3.090
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.